- Camrelizumab plus apatinib shows good response and manageable toxicities in previously treated patients with advanced cervical cancer.
Why this matters
- The activity of camrelizumab plus apatinib was superior to that reported for anti-programmed cell death protein 1/programmed death-ligand 1 (PD-L1) antibody or vascular endothelial growth factor pathway inhibitor monotherapy alone.
- Multicenter, phase 2 CLAP trial.
- 45 patients with advanced cervical cancer (median age, 51.0 years), who progressed after ≥1 line of systemic therapy, received camrelizumab plus apatinib.
- Funding: Chinese National Natural Science Foundation project.
- Median follow-up was 11.3 months.
- Objective response rate (ORR) was 55.6% (complete responses, 4.4%; partial responses, 51.1%).
- Median PFS was 8.8 months (95% CI, 5.6 months to not estimable).
- Median duration of response and median OS were not reached.
- Treatment-related grade 3/4 adverse event rate was 71.1%; most common were hypertension (24.4%), anemia (20.0%), and fatigue (15.6%).
- 33.3% of patients experienced potential immune-related toxicities; most common was hypothyroidism (22.2%).
- No difference in ORR was observed between patients with PD-L1-positive and PD-L1-negative tumors (69.0% vs 50.0%; P=.281).
- Open label, single group.